Harbour BioMed

We’re pleased to see Harbour BioMed featured by Simply Wall St as one of the “Undiscovered Gems in Asia with Strong Growth Potential.” According to the article, Harbour BioMed has achieved a 243% earnings increase year over year, significantly outperforming the biotech industry average. The report also noted our solid financial foundation, including positive free cash flow and shareholder equity, following the successful completion of a follow-on equity offering and share repurchase. As we continue to advance our innovative antibody therapeutics in immunology and oncology, we’re encouraged by the recognition of our performance and growth momentum in the global market. 🔗 Read the full article here: https://lnkd.in/e2rHwVdN #Biotech #Innovation #Immunology #Oncology #Growth

Harbour BioMed and Nona Biosciences have been featured in Nature’s Biopharma Dealmakers, highlighting our progress and collaborations that advance innovative therapeutics for patients worldwide. 👏 👏 We appreciate the recognition of our efforts to leverage our platforms and partnerships in shaping the next wave of biopharmaceutical innovation. 👉 Read the full article here: https://lnkd.in/eKR8bqXk #Innovation #Partnerships #DrugDiscovery #PipelineDevelopment

👏 👏 We are excited to announce our interim results for the first half of 2025, showcasing a period of exceptional performance and strategic advancement. These results further solidify our role as a cornerstone of global antibody drug development. Here are the key financial highlights: ✅ Strong Revenue Growth: Reported total revenue of US$101.3 million, representing a 3.27x year-over-year increase. ✅ Sustained Profitability: Achieved a net profit of US$73.0 million, a 51x year-over-year growth. This result marks a major milestone: 2.5 consecutive years of profitability. ✅ Solid Financial Foundation: Maintained a strong cash position with US$320 million in cash and cash equivalents, providing a robust platform for future innovation. Looking ahead, our solid financial foundation enables us to continue accelerating our growth trajectory, pushing the boundaries of innovation, and expanding our global impact. We will: 🌟 Advance our next-generation therapeutics pipeline, 🌟 Enhance our industry-leading technology platforms, 🌟 And drive breakthroughs that shape the future of healthcare. A heartfelt thank you to our dedicated team, visionary partners, and steadfast investors for your incredible support on this journey. Learn more in our full announcement: https://lnkd.in/gpGA892x #FinancialResults #Innovation #Growth #Investors

We are pleased to welcome Yajie Li as Chief Medical Officer at Harbour BioMed. 👏 👏 Ms. Li brings over a decade of experience in the pharmaceutical industry, with leadership roles in clinical development and regulatory affairs at multinational corporations and CROs including Merck, Johnson & Johnson and Parexel, as well as at Chinese biopharma companies such as GenSci, XuanZhu Biopharm, and Innovent. Prior to her industry career, she served for nine years as a Senior Medical Officer at the National Medical Products Administration of China (NMPA)/Center for Drug Evaluation (CDE), where she contributed to regulatory assessments across a broad range of therapeutic areas. In her new role, Ms. Li will lead clinical development, regulatory strategy, and medical affairs, supporting the continued growth of our pipeline and the delivery of impactful treatments to patients worldwide. Learn more: https://lnkd.in/gejyaNix #Leadership #ClinicalDevelopment #RegulatoryAffairs #Innovation

We are proud to share that Nona Biosciences, our wholly-owned subsidiary, has been nominated in the Best Startup category for the 2025 Prix Galien USA, one of the most prestigious honors in life sciences recognizing innovation and excellence in advancing human health. This nomination highlights Nona’s efforts to transform drug discovery and development through our HCAb antibody platform, integrated AI drug design capabilities, and end-to-end solutions that empower partners worldwide to bring novel therapies to patients faster.

We’re pleased to share that Harbour BioMed will present Phase II clinical data at #ESMO2025 on porustobart (HBM4003), our fully human heavy-chain-only anti-CTLA-4 antibody, in combination with tislelizumab for microsatellite stable (MSS) metastatic colorectal cancer (mCRC). MSS mCRC is a difficult-to-treat subtype with limited response to immune checkpoint inhibitors. Preclinical evidence supports the synergistic antitumor activity of CTLA-4 blockade combined with PD-(L)1 inhibition in mouse models. This multicenter Phase II study (NCT05167071) enrolled heavily pretreated, non-liver metastatic MSS mCRC patients to evaluate the safety and preliminary efficacy of this novel combination. 📍 ESMO Congress 2025 | Berlin 📅 October 17–21 ✏️ Title: Efficacy and Safety of HBM4003, an anti-CTLA-4 Antibody, Combined with Tislelizumab in MSS Metastatic Colorectal Cancer: A Multicenter, Phase II Study 📰 Poster # 807P 👤 Presenter: Dr. Frank Zheng Join us at ESMO 2025 to learn more about the promising findings from this Phase II study. Learn More: https://lnkd.in/gUkzX2Gj #ESMO2025 #HBM4003 #Porustobart #ColorectalCancer #ClinicalResearch #Oncology

We are pleased to share that, based on a preliminary review of the company’s unaudited management accounts for the first half of 2025, our total profit is expected to range between US$68 million (HK$532 million) and US$74 million (HK$579 million). The anticipated increase in profit is primarily driven by our continuing strategic partnerships with leading global pharmaceutical companies, such as AstraZeneca, as well as newly secured out-licensing and collaboration agreements for innovative products, which contributed significantly to revenue and are evolving into a normalized revenue stream of the company. These results reflect the strength of our business model and our commitment to translating scientific innovation into sustainable value. We look forward to building on this momentum through innovation and impactful collaborations. Learn more: https://lnkd.in/gnVg_cxD #HarbourBioMed #Innovation #StrategicPartnerships #Growth

👏 👏 We are pleased to share that our partner Windward Bio has initiated the POLARIS clinical study, a global, randomized, double-blind, placebo-controlled Phase 2 study evaluating the dosing, safety, and efficacy of HBM9378/WIN378 in patients with asthma. Initial data are expected in mid-2026. HBM9378/WIN378 is a potentially best-in-class, long-acting monoclonal antibody targeting TSLP - a key cytokine involved in the pathogenesis of asthma and other immunological conditions. This molecule has fully human sequences, offering a lower risk of immunogenicity and improved bioavailability compared to other TSLP-targeting therapies. It has been engineered to achieve a half-life extension and a silenced effector function and is subcutaneously administered. In a Phase 1 trial, HBM9378/WIN378 demonstrated an extended half-life, showed a low incidence of antidrug antibodies, and was safe and well tolerated up to the highest tested dose. Co-developed by Harbour BioMed and Kelun-Biotech, HBM9378/WIN378 is now being advanced globally by Windward Bio outside Greater China and select Asian territories. In parallel, it is also progressing in clinical development for COPD, with global trials expected in 2026. Learn More: https://lnkd.in/gPZm2btG #TSLP #Asthma #COPD #Immunology #AntibodyTherapeutics #ClinicalTrials

We’re pleased to share that Harbour BioMed has entered into a global strategic collaboration with Otsuka Pharmaceutical Co., Ltd. to advance BCMAxCD3 bispecific T-cell engagers for the treatment of autoimmune diseases.🤝 🤝 This collaboration grants Otsuka exclusive rights to develop, manufacture and commercialize HBM7020, a BCMAxCD3 bispecific T-cell engager globally, excluding Greater China. Harbour BioMed will receive $47 million in upfront and near-term payments, with the potential for up to $623 million in additional milestone payments, plus tiered royalties on future sales. This strategic collaboration highlights the strength of our proprietary Harbour Mice® and HBICE® platforms in enabling fully human bispecific antibodies with optimized safety and efficacy profiles. It also builds a foundation for potential future partnerships between the two companies in the T-cell engager area. We look forward to working with Otsuka to bring innovative treatment options to patients affected by autoimmune diseases around the world. Learn more:  https://lnkd.in/gTVmRGyn #Immunology #AutoimmuneDiseases #TCellEngager #BispecificAntibodies

🎉 We’re pleased to share that Youchen (YC) Chen has been appointed as Chief Financial Officer of Harbour BioMed!🎉 Since joining us in 2023, YC has taken on expanding leadership roles across Investor Relations, Corporate Development, Business Development, and Finance. His strategic vision and collaborative leadership have played a key role in advancing strategic transactions, global partnerships and alliances, as well as global financial management and operations. In his new role, YC will continue to guide our next phase of growth and contribute to building long-term value for the company and our stakeholders. Learn more: https://lnkd.in/gStZPjBh #Leadership #Biotech #Finance #StrategicGrowth #Innovation